Neil Rowan

Prof. Neil Rowan

Athlone Institute of Technology, Dublin Rd, Athlone, Co. Westmeath, Ireland
orcid
Technological University of the Shannon

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Science of The Total Environment
Verified
Journal Article
Closed access
Eoin McGillicuddyEoin McGillicuddy
Eoin McGillicuddy
IMI. Murray
I. Murray
SKS. Kavanagh
S. Kavanagh
LML. Morrison
L. Morrison
AFA. Fogarty
A. Fogarty
DMD. Morris
D. Morris

10 February 2021 in Trends in Food Science & Technology
Verified
Journal Article
Closed access
Charis GalanakisCharis Galanakis
Charis Galanakis
MRMyrto Rizou
Myrto Rizou
TATurki M.S. Aldawoud
Turki M.S. Aldawoud
İlknur Uçakİlknur Uçak
İlknur Uçak
Neil RowanNeil Rowan
Neil Rowan

1 July 2020 in Science of The Total Environment
Verified
Journal Article
Open access
Neil RowanNeil Rowan
Neil Rowan
JLJohn G. Laffey
John G. Laffey
Coronavirus (COVID-19) is highly infectious agent that causes fatal respiratory illnesses, which is of great global public health concern. Currently, there is no effective vaccine for tackling this COVID19 pandemic where disease countermeasures rely upon preventing or slowing person-to-person transmission. Specifically, there is increasing efforts to prevent or reduce transmission to front-line healthcare workers (HCW). However, there is growing international concern regarding the shortage in supply chain of critical one-time-use personal and protective equipment (PPE). PPE are heat sensitive and are not, by their manufacturer's design, intended for reprocessing. Most conventional sterilization technologies used in hospitals, or in terminal medical device sterilization providers, cannot effectively reprocess PPE due to the nature and severity of sterilization modalities. Contingency planning for PPE stock shortage is important. Solutions in the Republic of Ireland include use of smart communication channels to improve supply chain, bespoke production of PPE to meets gaps, along with least preferred option, use of sterilization or high-level disinfection for PPE reprocessing. Reprocessing PPE must consider material composition, functionality post treatment, along with appropriate disinfection. Following original manufacturer of PPE and regulatory guidance is important. Technologies deployed in the US, and for deployment in the Republic of Ireland, are eco-friendly, namely vaporised hydrogen peroxide (VH2O2), such as for filtering facepiece respirators and UV irradiation and High-level liquid disinfection (Actichlor+) is also been pursed in Ireland. Safeguarding supply chain of PPE will sustain vital healthcare provision and will help reduce mortality.

10 December 2020 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
EMEmma Murphy
Emma Murphy
Emanuele RezoagliEmanuele Rezoagli
Emanuele Rezoagli
Ian MajorIan Major
Ian Major
Neil RowanNeil Rowan
Neil Rowan
JLJohn Laffey
John Laffey
β-glucans are complex polysaccharides that are found in several plants and foods, including mushrooms. β-glucans display an array of potentially therapeutic properties. β-glucans have metabolic and gastro-intestinal effects, modulating the gut microbiome, altering lipid and glucose metabolism, reducing cholesterol, leading to their investigation as potential therapies for metabolic syndrome, obesity and diet regulation, gastrointestinal conditions such as irritable bowel, and to reduce cardiovascular and diabetes risk. β-glucans also have immune-modulating effects, leading to their investigation as adjuvant agents for cancers (solid and haematological malignancies), for immune-mediated conditions (e.g., allergic rhinitis, respiratory infections), and to enhance wound healing. The therapeutic potential of β-glucans is evidenced by the fact that two glucan isolates were licensed as drugs in Japan as immune-adjuvant therapy for cancer in 1980. Significant challenges exist to further clinical testing and translation of β-glucans. The diverse range of conditions for which β-glucans are in clinical testing underlines the incomplete understanding of the diverse mechanisms of action of β-glucans, a key knowledge gap. Furthermore, important differences appear to exist in the effects of apparently similar β-glucan preparations, which may be due to differences in sources and extraction procedures, another poorly understood issue. This review will describe the biology, potential mechanisms of action and key therapeutic targets being investigated in clinical trials of β-glucans and identify and discuss the key challenges to successful translation of this intriguing potential therapeutic.
1

1 December 2020 in Science of The Total Environment
Verified
Journal Article
Open access
Neil RowanNeil Rowan
Neil Rowan
CGCharis M. Galanakis
Charis M. Galanakis
COVID-19 pandemic is on a trajectory to cause catastrophic global upheaval with the potential to alter geopolitical and socio-economic norms. Many countries are frantically responding with staggering financial stimulus recovery initiatives. This opinion-paper reviews challenges, opportunities, and potential solutions for the post-COVID-19 era that focuses on intensive sustaining of agri-food supply chain in tandem with meeting the high demand for new green deal innovation. For example, the development of wet peatland innovation, known as Paludiculture, can intensively sustain and blend agri-food and green innovations that will help support COVID-19 pandemic transitioning. The future looks bright for the creation of new sustainability multi-actor innovation hubs that will support, connect, and enable businesses to recover and pivot beyond the COVID-19 pandemic. The nexus between first ‘Green Deal’ initiative supporting 64 selected European Startups and SMEs (European Innovation Council) and 43 Irish Disruptive Technology projects are addressed in the context of cross-cutting developments and relevance to COVID-19. Candidate areas for future consideration will focus on climate action, digitization, manufacturing, and sustainable food production, security, and waste mitigation. Recommendations are also provided to facilitate community transitioning, training, enterprise, and employment to low carbon economy.

1 March 2006 in Perspectives in Biology and Medicine
Verified
Journal Article
Closed access
PDF file
RSRichard Sullivan
Richard Sullivan
JSJohn E Smith
John E Smith
Neil RowanNeil Rowan
Neil Rowan
Modern medical practice relies heavily on the use of highly purified pharmaceutical compounds whose purity can be easily assessed and whose pharmaceutical activity and toxicity show clear structure-function relationships. In contrast, many herbal medicines contain mixtures of natural compounds that have not undergone detailed chemical analyses and whose mechanism of action is not known. Traditional folk medicine and ethno-pharmacology coupled to bioprospecting have been an important source of many anticancer agents as well as other medicines. With the current decline in the number of new molecular entities from the pharmaceutical industry, novel anticancer agents are being sought from traditional medicine. As the example of medicinal mushrooms demonstrates, however, translating traditional Eastern practices into acceptable evidence-based Western therapies is difficult. Different manufacturing standards, criteria of purity, and under-powered clinical trials make assessment of efficacy and toxicity by Western standards of clinical evidence difficult. Purified bioactive compounds derived from medicinal mushrooms are a potentially important new source of anticancer agents; their assimilation into Western drug discovery programs and clinical trials also provides a framework for the study and use of other traditional medicines.